CME

Immune Checkpoint Inhibitors for Advanced Bladder Cancer: Applying Clinical Advances and Elucidating Best Practices

Immune Checkpoint Inhibitors for Advanced Bladder Cancer: Applying Clinical Advances and Elucidating Best Practices

This activity is supported by an educational grant from Merck & Co, Inc.

Overview

Author(s)/Faculty: Daniel P. Petrylak, MD; David I. Quinn, MD, PhD, FRACP, FACP; Jonathan E. Rosenberg, MD; Walter M. Stadler, MD, FACP
Source: Healio - Hematology/Oncology Education Lab
Type: LectureArticles/Items: 5
Release Date: 4/3/2017Expiration Date: 4/2/2018
Credit Type: CMENumber of Credits: 1
Cost: FreeProvider: Vindico Medical Education
Advances in immunology and the advent of immune checkpoint blockade inhibition for advanced bladder cancer are poised to cause a paradigm shift in the near future. Therefore, it is of utmost importance that oncologists who treat patients with bladder cancer are ready and able to incorporate these agents into practice. In this CME activity, leading oncologists will discuss the latest treatment strategies, clinical advances, and targeted therapies for the treatment of advanced bladder cancer.

CME Information

page 1 of 8